Information
Full-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102
Original sourceAI Summary
Apellis Pharmaceuticals announced a full-year revenue of $689 million for 2025, driven by strong performances from SYFOVRE and EMPAVELI. As they plan regulatory submissions for a prefilled syringe of SYFOVRE and progress with EMPAVELI, positive market dynamics and cash reserves suggest potential for future growth.
Sentiment Rationale
The strong revenue performance and strategic initiatives indicate robust growth potential, historically leading to price appreciation during similar announcements.
Trading Thesis
APLS appears positioned for upside in 2026 based on revenue strength and regulatory developments.
Market-Moving
- Regulatory approval for the SYFOVRE prefilled syringe may boost sales.
- Continued strong uptake of EMPAVELI could enhance revenue forecasts.
- Improving cash position supports operational sustainability and growth initiatives.
- Positive results from ongoing trials could further catalyze stock performance.
Key Facts
- APLS reported $689 million in full-year 2025 net revenues.
- SYFOVRE generated $587 million; EMPAVELI contributed $102 million.
- Plans for regulatory submission of SYFOVRE prefilled syringe in mid-2026.
- EMPAVELI shows strong uptake with significant market penetration in C3G.
- Cash reserves expected to support operations through profitability.
Companies Mentioned
- Sobi (SOBI): Sobi triggered a $25 million milestone payment related to EMPAVELI.
- Beam Therapeutics (BEAM): Technology for APL-9099 being developed for future applications.
Corporate Developments
The news falls under 'Corporate Developments' as it highlights Apellis' operational performance and future plans, which are critical for investors assessing growth potential.